DARE
Dare Bioscience·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
High Gross Profit Margin
EPS Beats Expectation
Dark Cloud Cover
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DARE
Dare Bioscience, Inc.
A leader in women's health innovation
3655 Nobel Drive, Suite 260, San Diego, CA 92122
--
Dare Bioscience, Inc., was incorporated under the laws of the State of Delaware on November 28, 2005 under the name Tempo Pharmaceuticals, Inc. The company is an oncology-centric clinical-stage company that develops different therapies using its unique dynamic tumor targeting platform. Cerulean Pharma's nano-drug candidates include patented polymers that can be covalently attached to anticancer treatments, or payloads. Cerulean Pharma's leading product candidate, CRLX 101, targets dynamic tumors of nanopharmaceuticals in Phase 2 clinical development and has the ability to address unmet needs that existing cancer treatments have failed to address. The company's nanomedicine is polymer-based nanoparticles that are covalently attached to anti-cancer payloads. The company believes that the particle structures formed by these nano-drugs dynamically target tumors in three steps, a process that distinguishes the company's nano-drugs from other nano-pharmaceutical methods. First, the company's nanomedicine discovered a leak of new blood vessels in the tumor, which became a gateway into the tumor tissue. Second, Cerulean's nanomedicine is actively absorbed by tumor cells, and its nanomedicine is not easily removed from cancer cells due to volume. Third, nanopharmaceuticals provide the continuous release of anti-cancer payloads inside tumor cells.
Earnings Call
Q2/2025
Estimate EPS-0.58
Actual EPS-0.45
Estimate Revenue141.50K
Actual Revenue-21.17K
Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment
Aug 14,2025 07:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
DARE has released its 2025 Q3 earnings. EPS was reported at -0.28, versus the expected -0.38, beating expectations. The chart below visualizes how DARE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DARE has released its 2025 Q3 earnings report, with revenue of 2.26K, reflecting a YoY change of -94.57%, and net profit of -3.56M, showing a YoY change of 24.24%. The Sankey diagram below clearly presents DARE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
